D Vijay Pharma Private Limited Pharmaceutical Export Profile — India (DGFT 2022–2026)

Name: D Vijay Pharma Private Limited Pharmaceutical Export Portfolio Dataset — 2 Products, $25.8K FOB USD, India (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

D Vijay Pharma Private Limited — Pharmaceutical Exporter Profile (2026) | 2 Products, $25.8K Trade | TransData Nexus

D Vijay Pharma Private Limited

Indian Pharmaceutical Exporter · Brand Names & OTC Products Specialist · $25.8K Total Trade · DGFT Verified

D Vijay Pharma Private Limited is an Indian pharmaceutical exporter with a total trade value of $25.8K across 2 products in 2 therapeutic categories. Based on 17 verified export shipments from Indian Customs (DGFT) records, the company actively competes across multiple product segments. Top exports include Brufen ($21.9K), Atazanavir ($3.9K), .

D Vijay Pharma Private Limited — Export Portfolio & Destination Treemap

D Vijay Pharma Private Limited pharmaceutical export portfolio — 2 products across 2 therapeutic categories. Source: Indian Customs (DGFT).

Who is D Vijay Pharma Private Limited? — Company Overview & Market Position

D Vijay Pharma Private Limited, established on June 6, 2003, is a privately held pharmaceutical distribution company headquartered in Nashik, Maharashtra, India. The company operates under the Corporate Identification Number (CIN) U24230MH2003PTC140762 and is registered with the Registrar of Companies, Mumbai. Its authorized capital is ₹10 million, with a paid-up capital of ₹8.61 million.

The company specializes in the wholesale distribution of pharmaceutical products, including anti-cancer drugs, nephrology medications, and virology treatments. D Vijay Pharma Private Limited employs between 101 to 500 people and has an annual turnover ranging from ₹100 to ₹500 crore. The registered office is located at D Vijay House, Sr No 645/A/22, F P No.197 Tps II Old Agra Road, Near Hotel Samrat, CBS, Nashik, Maharashtra, 422002.

What Does D Vijay Pharma Private Limited Export? — Product Portfolio Analysis

Top Products by Export Value

1Brufen$21.9K 2Atazanavir

Product Portfolio — Top 2 by Export Value

D Vijay Pharma Private Limited exports 2 pharmaceutical products across 2 therapeutic categories.

#	Product	Category	Export Value	Shipments	Market Share	Rank
1	Brufen	Brand Names & OTC Products	$21.9K	12	0.5%	7
2	Atazanavir	Antiviral & HIV Medications	$3.9K	5	0.0%	8

D Vijay Pharma Private Limited exports 2 pharmaceutical products across 2 therapeutic categories with a total export value of $25.8K. The top category is Brand Names & OTC Products (84.8% of portfolio), followed by Antiviral & HIV Medications (15.2%), indicating a concentrated portfolio with the top 5 products accounting for 100.0% of total export value.

D Vijay Pharma Private Limited — Corporate Profile & Information

Headquarters, ownership, manufacturing facilities, and key leadership

1Corporate Overview

2Manufacturing Facilities

D Vijay Pharma Private Limited operates as a distributor and wholesaler of pharmaceutical products rather than a manufacturer. The company sources its products from various manufacturers, including top Indian and multinational companies with WHO GMP and USFDA-approved facilities. The distribution center in Nashik is regarded as the largest one-site pharmaceutical distribution center in the state of Maharashtra.

3Key Leadership

The leadership team of D Vijay Pharma Private Limited comprises:

Urmi Vijay Dinani – Managing Director
Upendra Jamnadas Dinani – Managing Director
Vijay Jamnadas Dinani – Director
Meera Upendra Dinani – Director

These individuals bring decades of experience in pharmaceutical distribution and marketing to the company.

TransData Nexus Research · Government registries, company filings, regulatory databasesMar 2026

Where Does D Vijay Pharma Private Limited Export? — Destination Intelligence

Regulated market presence, emerging market penetration, and geographic strategy

1Regulated Markets

D Vijay Pharma Private Limited's export activities are modest, with a total export value of $26,000 USD across 17 shipments from 2022 to 2026. The company's product portfolio includes Brufen and Atazanavir, with Brufen accounting for $22,000 USD and Atazanavir for $4,000 USD in export value. The primary therapeutic categories are Brand Names & OTC Products (84.8%) and Antiviral & HIV Medications (15.2%). The company does not hold a market leadership position in any category. The portfolio is highly concentrated, with the top five products comprising 100% of the export value.

2Emerging Markets

D Vijay Pharma Private Limited's export activities are limited, with a total export value of $26,000 USD across 17 shipments from 2022 to 2026. The company's product portfolio includes Brufen and Atazanavir, with Brufen accounting for $22,000 USD and Atazanavir for $4,000 USD in export value. The primary therapeutic categories are Brand Names & OTC Products (84.8%) and Antiviral & HIV Medications (15.2%). The company does not hold a market leadership position in any category. The portfolio is highly concentrated, with the top five products comprising 100% of the export value.

3Geographic Strategy

D Vijay Pharma Private Limited — Manufacturing & Regulatory Profile

FDA status, WHO-GMP certification, EU GMP compliance, and regulatory track record

1FDA Status

D Vijay Pharma Private Limited operates as a distributor and wholesaler of pharmaceutical products rather than a manufacturer. Therefore, the company does not have FDA facility registrations, approved ANDAs, or DMF filings. There is no available information regarding FDA inspections or observations for the company.

2WHO & EU GMP

D Vijay Pharma Private Limited sources its products from manufacturers with WHO GMP and USFDA-approved facilities. The company itself does not hold WHO prequalification or EU GMP certificates.

3CDSCO & Indian Regulatory

As a distributor, D Vijay Pharma Private Limited operates under the regulatory framework established by the Central Drugs Standard Control Organisation (CDSCO) and state drug controllers. The company holds the necessary licenses and approvals to distribute pharmaceutical products within India. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly available.

D Vijay Pharma Private Limited — Competitive Positioning Among Indian Pharma Exporters

Market share comparison, key differentiators, and strategic analysis

1Competitive Landscape

D Vijay Pharma Private Limited operates in a competitive pharmaceutical distribution market in India, with numerous players offering similar products and services. The company's modest export activities and highly concentrated product portfolio suggest limited engagement in the international market. A detailed market share comparison and head-to-head analysis with competitors are not available based on the provided information.

2Key Differentiators

D Vijay Pharma Private Limited's key differentiators include its extensive experience in pharmaceutical distribution, a diverse product portfolio encompassing critical care and specialty drugs, and a commitment to maintaining high distribution standards compliant with international WHO GSDP (Good Storage & Distribution Practices) standards.

3Strategic Position

D Vijay Pharma Private Limited focuses on the distribution of finished pharmaceutical formulations, including anti-cancer, nephrology, and virology drugs. The company's strategic direction emphasizes expanding its distribution network within India, particularly in Southern and Eastern Maharashtra, and exploring online retail operations to enhance accessibility and affordability for patients.

Buyer Due Diligence Brief — Evaluating D Vijay Pharma Private Limited as a Supplier

Track record assessment, certifications to verify, and pre-order checks

1Supplier Assessment

D Vijay Pharma Private Limited sources its products from manufacturers with WHO GMP and USFDA-approved facilities, ensuring compliance with international quality standards. The company's distribution center in Nashik is regarded as the largest one-site pharmaceutical distribution center in Maharashtra, indicating a robust supply chain infrastructure.

2Certifications to Verify

Importers should verify the following certifications to ensure product quality and regulatory compliance:

FDA Approval: Confirm that the manufacturing facilities hold FDA approvals for the specific products. Verification can be done through the FDA's official website or by contacting the manufacturer directly.

WHO GMP Certification: Ensure that the manufacturing facilities are certified by the World Health Organization's Good Manufacturing Practices. This can be verified through the WHO's official website or by requesting certification details from the manufacturer.

Frequently Asked Questions — D Vijay Pharma Private Limited

How many pharmaceutical products does D Vijay Pharma Private Limited export from India?

D Vijay Pharma Private Limited exports 2 pharmaceutical products across 2 therapeutic categories. The top exports are Brufen ($21.9K), Atazanavir ($3.9K). Total export value is $25.8K.

What is D Vijay Pharma Private Limited's total pharmaceutical export value?

D Vijay Pharma Private Limited's total pharmaceutical export value is $25.8K, based on 17 verified shipments recorded in Indian Customs (DGFT) data.

What therapeutic categories does D Vijay Pharma Private Limited cover?

D Vijay Pharma Private Limited exports across 2 therapeutic categories. The largest are Brand Names & OTC Products (84.8%, 1 products), Antiviral & HIV Medications (15.2%, 1 products).

Get Full D Vijay Pharma Private Limited Export Intelligence

Access shipment-level details, pricing data, buyer connections, product breakdown, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify manufacturer licensing, GMP certification, and export registration with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Market share calculated relative to total Indian pharmaceutical exports per product category. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.